Patient Square Capital LP Takes $1.38 Million Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

Patient Square Capital LP bought a new position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 32,000 shares of the company's stock, valued at approximately $1,383,000. Scholar Rock makes up approximately 0.5% of Patient Square Capital LP's investment portfolio, making the stock its 19th largest position.

A number of other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock valued at $34,000 after purchasing an additional 269 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Scholar Rock by 1.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock valued at $310,000 after purchasing an additional 379 shares during the last quarter. Amalgamated Bank lifted its stake in Scholar Rock by 30.6% in the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after purchasing an additional 620 shares during the last quarter. Global Retirement Partners LLC lifted its stake in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after purchasing an additional 766 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after purchasing an additional 1,031 shares during the last quarter. Institutional investors own 91.08% of the company's stock.

Insider Transactions at Scholar Rock

In other Scholar Rock news, CFO Edward H. Myles sold 7,809 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total transaction of $287,605.47. Following the completion of the transaction, the chief financial officer now owns 140,740 shares in the company, valued at $5,183,454.20. This trade represents a 5.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Tracey Sacco sold 5,000 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $32.83, for a total transaction of $164,150.00. Following the completion of the sale, the insider now owns 71,750 shares of the company's stock, valued at $2,355,552.50. This trade represents a 6.51% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 255,231 shares of company stock worth $9,220,236. Corporate insiders own 13.30% of the company's stock.

Scholar Rock Trading Down 2.0%

NASDAQ:SRRK traded down $0.60 during trading hours on Monday, reaching $29.95. The company's stock had a trading volume of 336,553 shares, compared to its average volume of 1,267,263. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -12.66 and a beta of 0.37. The firm has a 50-day simple moving average of $31.19 and a 200-day simple moving average of $35.96. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the company earned ($0.59) EPS. Research analysts expect that Scholar Rock Holding Co. will post -2.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wedbush restated an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $42.67.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.